Thermo Fisher Scientific Inc. is a prominent Massachusetts-based biotechnology and life sciences company with a market cap of $220 billion. It offers a wide range of products and services for research, diagnostics, and laboratory operations, serving various sectors globally. TMO stock has surged 21.8% over the past three months, outpacing the Health Care Select Sector SPDR Fund. Despite underperformance compared to a competitor, analysts remain optimistic about its prospects with a consensus rating of “Strong Buy” and a mean price target of $614.30 suggesting a 2.8% upside potential from current levels.

Read more at Barchart: Is TMO Outperforming the Health Care Sector?